Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Vertex Pharmaceuticals

Related VRTX
Early Global News: ON Semiconductor To Buy Fairchild, Stratasys And Autos, Google Maps Vs. Yelp
Vertex Receives Two EU Approvals for KALYDECO for Cystic Fibrosis

In a report published Friday, Deutsche Bank reiterated its Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX), but lowered its price target from $77.00 to $75.00.

Deutsche Bank noted, “We rate VRTX shares Buy on the back of potential success in their CF program targeting the homozygous F508del patients with VX-809 & Kalydeco. Our model suggests no value being assigned to HCV, no value to other CF gating mutations, and about 35% chance of success on 508del population. We model $1.4B revs, $1.2B expenses in 2013. Key questions remain Incivek & expense guidance. We model '13 down Incivek -35% & every $100M impacts DCF by $1.5/sh. Maintain Buy.”

Vertex Pharmaceuticals closed on Thursday at $39.10.

Latest Ratings for VRTX

Oct 2015H.C. WainwrightUpgradesNeutralBuy
Oct 2015Morgan StanleyUpgradesEqual-weightOverweight
Sep 2015Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (VRTX)

Get Benzinga's Newsletters